Nicholas RS - Search Results

1

Anticholinergics for urinary symptoms in multiple sclerosis.

Nicholas RS, Friede T, Hollis S, Young CA. Nicholas RS, et al. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD004193. doi: 10.1002/14651858.CD004193.pub2. Cochrane Database Syst Rev. 2009. Update in: Cochrane Database Syst Rev. 2015 Jun 05;(6):CD004193. doi: 10.1002/14651858.CD004193.pub3 PMID: 19160231 Updated. Review.

2

Multiple sclerosis.

Nicholas R, Chataway J. Nicholas R, et al. BMJ Clin Evid. 2007 Aug 15;2007:1202. BMJ Clin Evid. 2007. PMID: 19454107 Review.

3

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group. Cohen JA, et al. N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089954 Free article. Clinical Trial.

4

Bladder symptoms in multiple sclerosis: a review of pathophysiology and management.

Nicholas R, Young C, Friede T. Nicholas R, et al. Expert Opin Drug Saf. 2010 Nov;9(6):905-15. doi: 10.1517/14740338.2010.501793. Expert Opin Drug Saf. 2010. PMID: 20569078 Review.

5

A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis.

Chataway J, Nicholas R, Todd S, Miller DH, Parsons N, Valdés-Márquez E, Stallard N, Friede T. Chataway J, et al. Mult Scler. 2011 Jan;17(1):81-8. doi: 10.1177/1352458510382129. Epub 2010 Aug 26. Mult Scler. 2011. PMID: 20798135

6

Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: an application in multiple sclerosis.

Friede T, Parsons N, Stallard N, Todd S, Valdes Marquez E, Chataway J, Nicholas R. Friede T, et al. Stat Med. 2011 Jun 15;30(13):1528-40. doi: 10.1002/sim.4202. Epub 2011 Feb 22. Stat Med. 2011. PMID: 21341301

7

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA; TRANSFORMS Study Group. Khatri B, et al. Lancet Neurol. 2011 Jun;10(6):520-9. doi: 10.1016/S1474-4422(11)70099-0. Epub 2011 May 13. Lancet Neurol. 2011. PMID: 21571593 Clinical Trial.

8

Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design.

Nicholas R, Straube S, Schmidli H, Schneider S, Friede T. Nicholas R, et al. Mult Scler. 2011 Oct;17(10):1211-7. doi: 10.1177/1352458511406309. Epub 2011 May 17. Mult Scler. 2011. PMID: 21586489 Review.

9

Development of oral immunomodulatory agents in the management of multiple sclerosis.

Nicholas R, Giannetti P, Alsanousi A, Friede T, Muraro PA. Nicholas R, et al. Drug Des Devel Ther. 2011;5:255-74. doi: 10.2147/DDDT.S10498. Epub 2011 May 10. Drug Des Devel Ther. 2011. PMID: 21625416 Free PMC article. Review.

10

Multiple sclerosis.

Nicholas R, Chataway J. Nicholas R, et al. BMJ Clin Evid. 2009 May 14;2009:1202. BMJ Clin Evid. 2009. PMID: 21733201 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

207 results

Search Page

Filters